Adicet Bio, Inc. (ACET) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Adicet Bio, Inc. (ACET) closed at USD 5.14 on 2026-10-15, a change of -57.2 % over the past year, with a market capitalization of USD 42.78M.

Adicet Bio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Adicet Bio, Inc. key figures

Previous close

USD 5.14 (2026-10-15)

1-year change

-57.2 %

Market cap

USD 42.78M

Enterprise value

USD -56.14M

P/E ratio (trailing)

-0.44

P/E ratio (forward)

-1.13

EPS (trailing)

-10.42

EPS (forward)

-4.04

PEG ratio

n/a

Price to book

0.41

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.67

Employees

102

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Adicet Bio, Inc.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Adicet Bio, Inc. and compare it with other stocks.